Fig. 7

The antitumor effects of NZ001 in PDX model. a The MET protein expression in the 122 hepatocellular carcinoma samples were analyzed by IHC. The numbers on the top of the columes: the number of patients with different MET expression. b Vascular invasion rate in HCC samples from different MET expression groups. Significant differences were determined using chi-square test. c Immunofluorescence analysis was performed to detect the expression of HCC markers (AFP and GPC-3), fibroblast marker (a-SMA) and endothelial marker (CD34) in primary cancer cells from fresh HCC samples. d The effect of NZ001 on primary cancer cells from patients with HCC. The numbers on the top of the columes: the number of patients with different MET expression. e PDX models of HCC with MET-amplification and MET-overexpression were treated daily with vehicle or 30 mg/kg of NZ001 for 2 weeks. Tumor volumes were measured and recorded every 3 days from initial treatment to tumor harvest. f Kaplan–Meier survival curves of PDX models of HCC with MET-amplification and MET-overexpression treated daily with 30 mg/kg of NZ001. Data are shown as the mean ± SD. *: P < 0.05; **: P < 0.01; NS: No Significance